The Bio Report

In the United States, more than 100,000 people are on a transplant waiting list and many other simply do not qualify. In 2009, 25 people per day died while on the waiting list. Transplant procedures are costly and require lifelong use of immunotherapies. BioLife4D is seeking to disrupt organ transplantation with the development of bioprinted hearts produced using a patient’s own cells. The technology also has the potential to have an impact in other areas, such as drug discovery and development. We spoke to Steve Morris, founder and CEO of BioLife4D, about its effort to bioprint a transplantable human heart, a recent milestone it achieved to produce a mini-heart, and the range of challenges it must overcome to make its vision a commercial success.